First results of the phase Ib-II BladderGATE clinical trial: intravenous atezolizumab + intravesical bacillus Calmette-Guérin (BCG) upfront combination in BCG-naïve high risk non-muscle invasive bladder cancer patients

Saved in:

Bibliographic Details
Published in	European urology Vol. 85; p. S1701
Main Authors	Guerrero-Ramos, F., De Velasco, G., Duenas, M., Paramio, J., García, V.M., Gómez-Canizo, C., Rodríguez-Izquierdo, M., Hernández-Arroyo, M., Martín-Torres, M.P., Álvarez-Rodríguez, P., Suárez, C., Morales, L., Ponce, S., Rodríguez-Antolín, A., Castellano, D.
Format	Journal Article
Language	English
Published	01.03.2024
Online Access	Get full text

Loading…

More Information
ISSN:	0302-2838
DOI:	10.1016/S0302-2838(24)01302-2